| __timestamp | Eli Lilly and Company | Insmed Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 31073000 |
| Thursday, January 1, 2015 | 6533000000 | 43216000 |
| Friday, January 1, 2016 | 6452000000 | 50679000 |
| Sunday, January 1, 2017 | 6588100000 | 79171000 |
| Monday, January 1, 2018 | 5975100000 | 168218000 |
| Tuesday, January 1, 2019 | 6213800000 | 210796000 |
| Wednesday, January 1, 2020 | 6121200000 | 203613000 |
| Friday, January 1, 2021 | 6431600000 | 234273000 |
| Saturday, January 1, 2022 | 6440400000 | 265784000 |
| Sunday, January 1, 2023 | 6941200000 | 344501000 |
| Monday, January 1, 2024 | 8593800000 |
Cracking the code
In the competitive pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Eli Lilly and Company, a stalwart in the sector, has consistently maintained its SG&A expenses around $6.4 billion annually over the past decade. In contrast, Insmed Incorporated, a smaller player, has seen its SG&A costs rise from $31 million in 2014 to $345 million in 2023, marking a staggering increase of over 1,000%.
While Eli Lilly's expenses have shown a modest increase of about 5% from 2014 to 2023, Insmed's rapid growth in SG&A costs reflects its aggressive expansion strategy. This comparison highlights the different financial strategies employed by established giants and emerging companies in the pharmaceutical landscape. Understanding these dynamics is essential for investors and industry analysts alike.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Zoetis Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs argenx SE Trends and Insights
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Perrigo Company plc
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Insmed Incorporated
Insmed Incorporated vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Insmed Incorporated and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Insmed Incorporated vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Geron Corporation